tbuckley/cabot-search huggingface dataset:
SYSTEMIC REACTION TO ORAL FUSO-SPIROCHETOSIS WITHOUT LOCAL LESIONS
Authors: William H. Barrow
Journal: Annals of Internal Medicine (1938)

Article1 October 1938SYSTEMIC REACTION TO ORAL FUSO-SPIROCHETOSIS WITHOUT LOCAL LESIONSWILLIAM H. BARROW, M.D., F.A.C.P.WILLIAM H. BARROW, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-12-4-508 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOral spirochetes and fusiform bacilli were first identified in the 1890's as the pathogenic organisms in ulcero-membranous diseases of the mouth and throat. The work of Veillon, Plaut, and Vincent was quickly confirmed by others and thereafter fuso-spirochetal angina and stomatitis were seldom mentioned in the literature except in connection with some unusual or interesting complication or with reference to some new form of treatment. The disease has been calledVincent's anginaorVincent's infection, ulcero-membranous gingivitis, trench mouth, andspiro-fusillary gingivitis. As the nomenclature would indicate the disease has been and is described as being characterized by ulceration or...References1. SMITH DT: Oral spirochetes and related organisms in fuso-spirochetal disease, 1932, Williams and Wilkins, Baltimore, Chapter 9-10. Google Scholar2. MILLEREPSTEIN HEN: Vincent's angina. The significance of fusiform bacilli and spirilla in mucous membrane lesions, California and West. Med., 1926, xxiv, 633. Google Scholar3. KOLMER JA: Bismuth arsphenamine sulphonate (bismarsen) in the treatment of syphilis and of other spirochetic infections, Arch. Dermat. and Syph., 1930, xxi, 394. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: San Diego, California*Read before the General Medicine Section of the California Medical Association at the sixty-sixth annual session, Del Monte, May 2-6, 1937. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1938Volume 12, Issue 4Page: 508-515KeywordsAnginaInfectious diseasesLesionsMouthOral medicinePathogensPharynxSpirochetesUlcers Issue Published: 1 October 1938 PDF downloadLoading ...
Listen Doctor, the Patient Just Might Be Right
Authors: Renu Mansukhani
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
HEMOCHROMATOSIS; A CASE REPORT WITH NECROPSY
Authors: P. A. Gray
Journal: Annals of Internal Medicine (1943)

Case Reports1 September 1943HEMOCHROMATOSIS; A CASE REPORT WITH NECROPSYP. A. GRAY, M.D., F.A.C.P.P. A. GRAY, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-19-3-501 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe clinical features of hemochromatosis as described in Sheldon's1excellent monograph include (1) a predominant occurrence between 35 and 60 years of age, (2) a predilection for the male sex, (3) a familial background, (4) a short life expectancy (18½ months), and (5) a diagnostic triad of symptoms: pigmentation of the skin, diabetes mellitus, and cirrhosis of the liver. Butt and Wilder2and Lawrence3reported a longer survival period than this among their cases and predicted a reduction of the high mortality (50 per cent) noted by Sheldon1due to diabetic coma. They felt that improved treatment of the associated...Bibliography1. SHELDON JH: Hemochromatosis, 1935, Oxford University Press, New York City. Google Scholar2. BUTTWILDER HRRM: Hemochromatosis, Arch. Path., 1938, xxvi, 262-273. Google Scholar3. LAWRENCE RD: The prognosis of hemochromatosis, Lancet, 1936, ii, 1055-1056. Google Scholar4. PLUMMERWILDERALLEN WARME: Personal communication. Google Scholar5. GRAYBURTNESS PAHI: Hypoglycemic headache, Endocrinology, 1935, xix, 549-560. CrossrefGoogle Scholar6. FOLINMALMROS OH: Improved form of Folin's micro method for blood sugar determinations, Jr. Biol. Chem., 1929, lxxxiii, 115-120. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Santa Barbara, California*Received for publication September 13, 1941. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPHLEBOTOMY FOR HÆMOCHROMATOSIS EFFECT OF REMOVING 52 PINTS OF BLOOD IN SIXTEEN MONTHSThe heart in hemochromatosis 1 September 1943Volume 19, Issue 3Page: 501-506KeywordsCirrhosisComaDiabetes mellitusHemochromatosisLife expectancyLiverMortality Issue Published: 1 September 1943 PDF downloadLoading ...
Abstract 1761: PDE10, a novel therapeutic target for lung cancer
Authors: Bing Zhu, Nan Li, Veronica Ramirez-Alcantara, Joshua Canzoneri, Evrim Gurpinar, Alexandra Fajardo, Kevin Lee, Sara Sigler, Bernard Gary, Meagan Thomas, Adam Keeton, Xi Chen, William Grizzle, Gary Piazza
Journal: Cancer Research (2014)

Abstract Phosphodiesterase 10A (PDE10) is a relatively new PDE isozyme that has been mostly studied in the brain as a therapeutic target for certain psychiatric and neurological conditions, but has not been associated with tumorigenesis. While other investigators have reported low levels of PDE10 in most adult peripheral tissues, we found a large percentage of human lung tumors express high levels of PDE10 compared with normal lung tissue as determined by real-time PCR analysis of cDNA arrays. Statistical analysis revealed that 68% of lung tumors (n=19) displayed more than two-fold increase compared with normal lung tissue, while 26% showed greater than a 10-fold difference. High levels of PDE10 mRNA and protein were also found in human non-small cell lung cancer (NSCLC) cell lines compared with normal airway epithelial cells. PDE10 knockdown by small interference RNA significantly suppressed lung tumor cell growth, as did PDE10 selective inhibitors, papaverine, PQ-10 and Pf-2545920. A novel PDE10 inhibitor, MCI-020 also inhibited the growth of NSCLC cells with a high degree of selectivity for tumor cells. Consistent with a mechanism involving PDE10 inhibition, PQ-10 and MCI-020 increased cGMP levels in a concentration-dependent manner as determined using a cGMP biosensor assay. MCI-020 also activated cGMP-dependent protein kinase (PKG) in NSCLCs as evident by increased phosphorylation of VASP-Serine239. With attractive pharmacokinetic properties, MCI-020 was studied further and found to display an unusual characteristic of achieving high concentrations in lung tissue compared with other tissues and plasma following oral administration. MCI-020 was well tolerated in mice at a dose of 250 mg/kg bid and strongly inhibited tumor formation in an orthotopic model of lung cancer at a dose of 150 mg/kg bid. These observations suggest that PDE10 is essential for lung tumor cell growth and represents a novel therapeutic target for lung cancer. Citation Format: Bing Zhu, Nan Li, Veronica Ramirez-Alcantara, Joshua Canzoneri, Evrim Gurpinar, Alexandra Fajardo, Kevin Lee, Sara Sigler, Bernard Gary, Meagan Thomas, Adam Keeton, Xi Chen, William Grizzle, Gary Piazza. PDE10, a novel therapeutic target for lung cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1761. doi:10.1158/1538-7445.AM2014-1761
Peripheral blood cells from children with RASopathies show enhanced spontaneous colonies growth in vitro and hyperactive RAS signaling
Authors: G Gaipa, C Bugarin, P Cianci, J Sarno, P Bonaccorso, A Biondi, A Selicorni
Journal: Blood Cancer Journal (2015)

Abstract Germline mutations in genes coding for molecules involved in the RAS/RAF/MEK/ERK pathway are the hallmarks of a newly classified family of autosomal dominant syndromes termed RASopathies. Myeloproliferative disorders (MPDs), in particular, juvenile myelomonocytic leukemia, can lead to potentially severe complications in children with Noonan syndrome (NS). We studied 27 children with NS or other RASopathies and 35 age-matched children as control subjects. Peripheral blood (PB) cells from these patients were studied for in vitro colony-forming units (CFUs) activity, as well as for intracellular phosphosignaling. Higher spontaneous growth of both burst-forming units-erythroid (BFU-E) and CFU-granulocyte/macrophage (CFU-GM) colonies from RAS-mutated patients were observed as compared with control subjects. We also observed a significantly higher amount of GM-colony-stimulating factor-induced p-ERK in children with RASopathies. Our findings demonstrate for the first time that PB cells isolated from children suffering from NS or other RASopathies without MPD display enhanced BFU-E and CFU-GM colony formation in vitro . The biological significance of these findings clearly awaits further studies. Collectively, our data provide a basis for further investigating of only partially characterized hematological alterations present in children suffering from RASopathies, and may provide new markers for progression toward malignant MPD in these patients.
They're Not Just Little Adults: Special Considerations in Pediatric Clinical Ethics Consultation
Authors: Alexander A. Kon
Journal: The American Journal of Bioethics (2015)

Not Go Gentle Into That Good Night” (Thomas 1952) captures the goal of the investigators and families of patients at St. Jude’s. Theirs—like Thomas’s exaltation to his dying father—represents a noble cause. It is, however, not a good template for determining the scope of ethics consults in pediatrics. Such consults, particularly regarding neonates (Paris, Schreiber, and Moreland 2011), are more varied and more challenging than those reported at St. Jude Hospital. &
Mechanism of Asymmetric Leaflet Tethering in Ischemic Mitral Regurgitation
Authors: Kitae Kim, Shuichiro Kaji, Yoshimori An, Hidetoshi Yoshitani, Masaaki Takeuchi, Robert A. Levine, Yutaka Otsuji, Yutaka Furukawa
Journal: JACC. Cardiovascular imaging (2012)
Abstract P2-11-01: Treatment of metastatic breast cancer patients by community health practitioners: Practice pattern and competence assessments
Authors: Sara R Fagerlie, Alison Heintz, Maureen Haas
Journal: Cancer Research (2015)

Abstract Background: The complexity of current treatment and management for patients with metastatic breast cancer continues to rise. The volume and pace of scientific advances make it challenging for the community practitioner to stay abreast of optimal patient care. Education is key in disseminating critical information to practitioners and allows professional reflection of appropriate therapeutic decision making and peer discussion. Understanding the base knowledge, competence, and current practice patterns of the community practitioner is critical to identification community needs and implementation of education that impacts patient care. Methods: During 2013 and 2014, educational outcomes assessments were gathered during 2 education programs consisting of 47 live independent continuing medical education (CME) activities held within community practices across the USA. Participants were asked a series of case-based questions via an audience response system to assess baseline knowledge, competence, and identify practice patterns Assessments were repeated following the 1-hour CME certified activity. Long-term assessment was conducted electronically 6-weeks following the educational initiative. Results: The programs educated 958 practitioners, including 515 physicians. Practice patterns for frontline treatment varied at baseline. Education resulted in treatment more highly aligned with practice guidelines and recent advances. At baseline 75% of practitioners and 30% of the physician target audience were unable to identify appropriate next steps in a borderline HER2+ patient. The education reduced the gap by 25%. 6-weeks following the activity 100% of the assessed physician target audience agreed or strongly agreed that the education influenced their interpretation of HER2 testing. Practice gaps in practitioners ability to identify, recall, and interpret practice changing clinical trials were also identified. Newness of treatment data, lack of reimbursement, and treatment side effects were the most common barriers identified in applying the education into clinical practice. Conclusions: The results highlight the diversity of current clinical practice in the community practice setting for patients with metastatic breast cancer and the positive impact of focused education. Knowledge and competence practice gaps were identified to pinpoint specific areas of benefit for the community practice setting in the treatment of patients with metastatic breast cancer. Citation Format: Sara R Fagerlie, Alison Heintz, Maureen Haas. Treatment of metastatic breast cancer patients by community health practitioners: Practice pattern and competence assessments [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-11-01.
Private Efforts Pick Up Stem Cell Slack
Authors: Brian Vastag
Journal: JAMA (2004)

THIRTY MONTHS AFTER PRESIDENT Bush banned federal funding for research on embryonic stem cells created after August 9, 2001, scientists and advocates are sidestepping the restrictions with millions of private and state dollars. At the same time, new research on adult stem cells—touted by embryonic cell opponents as a viable alternative for development of advanced tissue-replacement technologies—suggests they are less flexible than once imagined. For the first time since Bush announced the policy, embryonic stem cell proponents sound upbeat, propelled by a movement in Congress to open the floodgates of federal funding. In March, 70 members of Congress wrote the White House, telling Bush that unless he eases restrictions, they intend to push legislation that will accomplish the same. Led by Rep Michael Castle (R, Del), the coalition argues that the current policy has been “unintentionally restrictive” and that rapid advances in the field require flexible policies.
Abstract 2854: Clinical significance of inhibin beta A expression in gastric cancer
Authors: Takashi Oshima, Toshio Imada, Naoto Yamamoto, Tsutomu Sato, Norio Yukawa, Manabu Shiozawa, Takaki Yoshikawa, Yasushi Rino, Chikara Kunisaki, Makoto Akaike, Munetaka Masuda
Journal: Cancer Research (2014)

Abstract Objective: Inhibin beta A (INHBA), a glycoprotein belonging to the TGF-β superfamily, has recently been reported to participate in cancer-cell proliferation. We comprehensively studied the ratio of INHBA gene expression in gastric cancer tissue to that in adjacent normal mucosa by DNA microarray analysis and found that that INHBA gene expression was 12.8-fold higher in gastric cancer tissue. To extend our previous results, we investigated the clinical significance of INHBA gene expression in gastric cancer. Methods: We studied 227 patients with gastric cancer followed up for at least 5 years postoperatively. The disease stage was I in 29 patients, II in 59, III in 88, and IV in 51. Of the 147 patients with stage II or III disease, 80 postoperatively received S-1 adjuvant chemotherapy, and 67 received surgery alone. We extracted mRNA from frozen specimens of gastric cancer and adjacent normal mucosa from these patients, calculated relative expression levels of the INHBA gene (quantitative PCR analysis), and studied the relations of INHBA expression to clinicopathological factors and treatment outcomes. We also examined the relation between S-1 adjuvant chemotherapy and INHBA gene expression in patients with Stage II or III gastric cancer, for which adjuvant chemotherapy is standard treatment. Results: INHBA gene expression was significantly higher in gastric cancer than in adjacent normal mucosa (P&amp;lt;0.0001) and was significantly related to the clinicopathological factors of invasion depth, disease stage, and vascular invasion. High INHBA gene expression was significantly related to poor outcomes (P=0.0320). In stage II and III gastric cancer, survival rates did not differ according to INHBA gene expression in patients who underwent surgery alone. In contrast, survival was significantly poorer in gastric cancer with high INHBA gene expression in patients who received S-1 adjuvant chemotherapy (P=0.003). Conclusions: INHBA gene expression was suggested to be a useful predictor of poor outcomes in patients with resected gastric cancer. In patients given S-1 adjuvant chemotherapy, INHBA gene expression may be a useful biomarker. Citation Format: Takashi Oshima, Toshio Imada, Naoto Yamamoto, Tsutomu Sato, Norio Yukawa, Manabu Shiozawa, Takaki Yoshikawa, Yasushi Rino, Chikara Kunisaki, Makoto Akaike, Munetaka Masuda. Clinical significance of inhibin beta A expression in gastric cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2854. doi:10.1158/1538-7445.AM2014-2854
Grand Rounds--Hammersmith Hospitals: Distinguishing acute disseminated encephalomyelitis from multiple sclerosis
Authors: R W Orrell
Journal: BMJ (1996)

The use of these terms is further described in table 2, which uses these terms to describe a range of different risks, some familiar, some less so.Where precisely a risk falls within this classification is often a matter of debate.Risks may vary from time to time, with changing circumstances and information on the level of risk.It is possible, for example, for new research and knowledge to change the level of risk. COMMUNICATING RISKThe foregoing discussion leads naturally to a consid- eration of how best to communicate the level of risk associated with a particular health or healthcare issue to the public.' 12The media have an important responsi- bility here.A number of guidelines have been described and they include: the importance of credible sources of advice, openness, sharing uncertainty, the need to accept the public as parmers, careful planning, listening to concerns, coordinating with other credible sources, and the importance of meeting the needs of the media.This preliminary classification of the terminology relating to risk should be the subject of further debate.However, it does emphasise the importance of ensuring that the public are full partners in the process of risk assessment and management, and it is only with such involvement that progress can be made.
Abstract 107: Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair
Authors: Ryuji Hamamoto, Kenbun Sone, Yusuka Nakamura
Journal: Cancer Research (2015)

Abstract γ-H2AX, the serine 139-phosphorylated form of the histone protein H2AX, is a marker of activation of the DNA damage machinery and is often overexpressed in many malignancies. Although γ-H2AX deregulation in cancer has previously been reported, the relevant molecular functions during carcinogenesis as well as its relationship with other histone modifications are still largely unknown. In the present study, we found that the histone methyltransferase Suppressor of Variegation 3-9 Homolog 2 (SUV39H2) methylated lysine 134 on histone H2AX, which is located in a unique portion of H2AX among the histone H2A family. When lysine 134 of histone H2AX was substituted to alanine, the amount of γ-H2AX production was significantly abolished. We also found lower γ-H2AX activity after introduction of the double-strand breakage in Suv39h2-double null cells or when SUV39H2 was knocked down. Concordantly, tissue microarray analysis of clinical lung tissues demonstrated a significantly positive correlation between K134-methylated H2AX and γ-H2AX levels. Furthermore, introduction of K134-substituted histone H2AX enhanced radio- and chemo-sensitivity of cancer cells, implying a critical role of methylation on the regulation of γ-H2AX production and the DNA repair pathways in cancer cells. This is the first report describing the functions of methylation on histone H2AX and its important role in the regulation of γ-H2AX production in cancer. Citation Format: Ryuji Hamamoto, Kenbun Sone, Yusuka Nakamura. Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 107. doi:10.1158/1538-7445.AM2015-107